Last reviewed · How we verify

NCT05062629

United States Hypophosphatasia Molecular Research Center

Active, enrolled Last updated 14 April 2026
What this trial tests

trial testing Whole Genome Sequencing in Hypophosphatasia in 66 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
24 August 2021
Primary endpoint
30 April 2026
30 June 2026

Quick facts

Lead sponsorChildren's Mercy Hospital Kansas City
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment66
Start date24 August 2021
Primary completion30 April 2026
Estimated completion30 June 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Children's Mercy Hospital Kansas City

Who can join

Eligibility, any sex, with Hypophosphatasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to determine if cryptic alterations exist within or near to the ALPL gene in patients with a clinical diagnosis of hypophosphatasia, but without identifiable alteration on commercial testing. Additionally, the study aims to characterize functional effects of certain variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Whole Genome Sequencing

Trials testing the same drug.

Other recruiting trials for Hypophosphatasia

Currently open trials in the same condition.

Other Children's Mercy Hospital Kansas City trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05062629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing